Q Fever Market

The bacterium Coxiella burnetii is the source of the zoonotic illness known as Q fever. Although it predominantly affects animals, the sickness can also spread to people. Inhaling polluted dust or air or consuming contaminated food are two common ways to get Q fever.

The size of the world market for Q fever was estimated at USD **Million in 2018 and is projected to increase at a CAGR of **% between 2018 and 2031.

The market for the diagnosis, care, and avoidance of Q fever in both humans and animals is called the "Q fever market." Since Q fever is not an illness that needs to be reported in many nations, it is challenging to accurately determine the market's size. The market size is anticipated to increase due to rising disease awareness and the availability of novel diagnostic and therapeutic alternatives.

Humans typically contract Q fever by inhaling contaminated air or dust from diseased animals. In extreme circumstances, the illness can cause severe complications and flu-like symptoms. A persistent infection risk also exists, which might result in long-term health issues.

Market expansion is anticipated to be fueled by rising Q fever prevalence, more public awareness of the condition, and the creation of new diagnostic and therapeutic alternatives. Additionally, expanding market players' access to prospects would likely result from expenditures in research and development activities to create efficient vaccines and medicines.

Abbott Laboratories, Thermo Fisher Scientific, Inc., Merck KGaA, DiaSorin S.p.A., Creative Diagnostics, Bio-Rad Laboratories, Inc., Luminex Corporation, Alere Inc., and BioMérieux SA are a few of the major companies active in the Q fever industry.